Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
June 20, 2024Cancer LettersOpen Access

CDK4/6 inhibition augments anti-tumor efficacy of XPO1 inhibitor selinexor in natural killer/T-cell lymphoma

View Full Paper
Ask AI
Bookmark
Share

Authors

YWYali WangFujian University of Traditional Chinese MedicineJCJianfeng ChenSun Yat-sen UniversityYGYan GaoJiangsu University

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Wang et al. (2024) studied this question.

synapsesocial.com/papers/68e63e39b6db6435875d0518https://doi.org/10.1016/j.canlet.2024.217080
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Cyclin D1/Cdk4 regulates retinoblastoma protein-mediated cell cycle arrest by site-specific phosphorylation.1997 · 407 citations
  2. 2CDK4/6 Inhibition Augments Antitumor Immunity by Enhancing T-cell Activation2017 · 804 citations
  3. 3Promising SINEs for Embargoing Nuclear–Cytoplasmic Export as an Anticancer Strategy2014 · 112 citations
  4. 4Phase II Trial of Concurrent Radiation and Weekly Cisplatin Followed by VIPD Chemotherapy in Newly Diagnosed, Stage IE to IIE, Nasal, Extranodal NK/T-Cell Lymphoma: Consortium for Improving Survival of Lymphoma Study2009 · 344 citations
  5. 5Selinexor inhibits growth of patient derived chordomas in vivo as a single agent and in combination with abemaciclib through diverse mechanisms2022 · 9 citations